Companies › Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
16 active drug programs in 31 registered trials: 15 Phase 1, 10 Phase 2, 6 Phase 3; Oncology, Immunology, Hematology, Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TQB2102 for injection HER2-targeting antibody-drug conjugate (ADC) with dual epitope targeting (ECD2 and ECD4) | ERBB2 | Phase 3 | HER2-positive Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Gynecological Tumors … | Nov 2026 |
| TQB2930 injection Dual-epitope HER2 antibody targeting ECD2 and ECD4 epitopes | ERBB2 | Phase 3 | HER2-positive Advanced Breast Cancer; Colorectal Cancer; Advanced Solid Tumor | Jun 2027 |
| TQH3906 Capsules Highly selective TYK2 allosteric inhibitor targeting the JH2 domain, blocking IL-23 and Ty | TYK2 | Phase 3 | Psoriasis; Psoriatic Arthritis; Inflammatory Bowel Diseases | Jul 2027 |
| Recombinant human coagulation factor VIII for injection Recombinant human coagulation factor VIII (replacement therapy) | F8 | Phase 3 | Hemophilia A | – |
| TQB2868 injection Anti-PD-1/TGF-βRII bifunctional fusion protein | PDCD1, TGFBR2 | Phase 2 | Pancreatic Neoplasms | Nov 2026 |
| Benmelstobart injection Humanized monoclonal antibody targeting PD-L1 | CD274 | Phase 2 | Non-Small Cell Lung Cancer | Dec 2026 |
| TQA2225/AP025 FGF21-Fc fusion protein | FGF21 | Phase 2 | Non-alcoholic Steatohepatitis | Dec 2026 |
| TQC2938 humanized monoclonal antibody interfering with signal cascade | – | Phase 2 | Chronic Obstructive Pulmonary Disease | Mar 2027 |
| TQB2916 Injection | – | Phase 2 | Pancreatic Cancer | Aug 2027 |
| TQB2922 for injection anti-EGFR/c-Met bispecific antibody | EGFR, MET | Phase 1 | Advanced Cancer; RAS/BRAF Wild Type Colorectal Cancer | Dec 2026 |
| TQB2934 Anti-CD3 × BCMA double-specific antibody (bispecific T-cell engager) | CD3, BCMA | Phase 1 | Multiple Myeloma | Oct 2027 |
| TQB6411 injection EGFR/c-Met dual-targeting antibody-drug conjugate (ADC) | EGFR, MET | Phase 1 | Advanced Malignant Tumors | Dec 2027 |
| TQB2029 for injection bispecific antibody targeting GPRC5D and CD3; recruits and activates CD3+ T cells to kill | GPRC5D, CD3 | Phase 1 | Multiple Myeloma | Mar 2028 |
| TQB2101 for Injection anti-ROR1 antibody-drug conjugate | ROR1 | Phase 1 | Advanced Hematologic Malignancies | Jun 2028 |
| LM-108 injection Monoclonal antibody that selectively depletes regulatory T cells infiltrating tumor sites | – | Phase 1 | Advanced Solid Tumor | – |
| TQH2929 Injection humanized monoclonal antibody interfering with signal cascade | – | Phase 1 | Generalized Pustular Psoriasis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06433531 | TQH2929 Injection | Phase 1 | Generalized Pustular Psoriasis | Immunology | Jul 2025 |
| NCT06825494 | LM-108 injection | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2026 |
| NCT06297655 | Recombinant human coagulation factor VIII for injection | Phase 3 | Hemophilia A | Hematology | Jul 2026 |
| NCT06767813 | TQB2868 injection | Phase 2 | Pancreatic Neoplasms | Oncology | Nov 2026 |
| NCT06798207 | TQB2102 for injection | Phase 2 | Gynecological Tumors | Oncology | Nov 2026 |
| NCT06188624 | TQB2922 for injection | Phase 1 | Advanced Cancer | Oncology | Dec 2026 |
| NCT06569524 | TQA2225/AP025 | Phase 2 | Non-alcoholic Steatohepatitis | Gastroenterology | Dec 2026 |
| NCT06496490 | Benmelstobart injection | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06496490 | TQB2102 for injection | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06789289 | TQC2938 | Phase 2 | Chronic Obstructive Pulmonary Disease | Respiratory | Mar 2027 |
| NCT06431490 | TQB2102 for injection | Phase 1 | Biliary Tract Cancer | Oncology | May 2027 |
| NCT07653685 | TQB2930 injection | Phase 1 | Colorectal Cancer | Oncology | Jun 2027 |
| NCT07044908 | TQB2922 for injection | Phase 1 | RAS/BRAF Wild Type Colorectal Cancer | Oncology | Jul 2027 |
| NCT07044908 | TQB2922 for injection | Phase 1 | RAS/BRAF Wild Type Colorectal Cancer | Oncology | Jul 2027 |
| NCT06754891 | TQH3906 Capsules | Phase 1 | Inflammatory Bowel Diseases | Immunology | Jul 2027 |
| NCT05735496 | TQB2102 for injection | Phase 1 | Advanced Cancer | Oncology | Jul 2027 |
| NCT07406035 | TQH3906 Capsules | Phase 2 | Psoriatic Arthritis | Immunology | Aug 2027 |
| NCT06962267 | TQB2916 Injection | Phase 2 | Pancreatic Cancer | Oncology | Aug 2027 |
| NCT07724366 | TQH3906 Capsules | Phase 3 | Psoriasis | Immunology | Sep 2027 |
| NCT07043725 | TQB2102 for injection | Phase 3 | HER2-positive Breast Cancer | Oncology | Sep 2027 |
| NCT06767800 | TQB2102 for injection | Phase 2 | Gastroesophageal Adenocarcinoma | Oncology | Sep 2027 |
| NCT07179679 | TQB2934 | Phase 1 | Multiple Myeloma | Oncology | Oct 2027 |
| NCT07043751 | TQB6411 injection | Phase 1 | Advanced Malignant Tumors | Oncology | Dec 2027 |
| NCT06700395 | TQB2029 for injection | Phase 1 | Multiple Myeloma | Oncology | Mar 2028 |
| NCT07008976 | TQB2102 for injection | Phase 3 | Metastatic Breast Cancer | Oncology | Mar 2028 |
| NCT07512583 | TQB2930 injection | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2028 |
| NCT07512583 | TQB2930 injection | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2028 |
| NCT07113925 | TQB2101 for Injection | Phase 1 | Advanced Hematologic Malignancies | Oncology | Jun 2028 |
| NCT06452706 | TQB2102 for injection | Phase 2 | Breast Cancer | Oncology | Jun 2028 |
| NCT07047365 | TQB2930 injection | Phase 3 | HER2-positive Advanced Breast Cancer | Oncology | Jun 2028 |
| NCT07003074 | TQB2102 for injection | Phase 3 | Breast Cancer | Oncology | Jul 2029 |
EGFR (2) MET (2) CD3 (2) ERBB2 (2) BCMA (1) TYK2 (1) F8 (1) ROR1 (1) FGF21 (1) CD274 (1) PDCD1 (1) TGFBR2 (1)
AstraZeneca Beijing Biotech Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Johnson & Johnson (Janssen) AbbVie Pfizer Roche Yuhan Betta Pharmaceuticals
Shanghai Henlius Biotech Sichuan Baili Pharmaceutical Sichuan Kelun-Biotech Biopharmaceutical Merck KGaA Shenyang Sunshine Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.